Boehringer Ingelheim

Boehringer Ingelheim, established in 1885, is a global pharmaceutical company headquartered in Ingelheim am Rhein, Germany. It focuses on researching, developing, manufacturing, and marketing innovative healthcare products for both humans and animals. The company's venture fund, founded in 2010, invests in groundbreaking biotechnology companies, targeting significant enhancements in patient care through pioneering science. It primarily focuses on immuno-oncology, regenerative medicine, infectious diseases, and digital health, with investments ranging from EUR 0.5 to EUR 15 million, and an investment horizon of 5 to 7 years.